Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer Maintained with a Long-Term Analysis
Long-term outcomes and exploratory analyses from the BILCAP study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma
It also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients with dMMR in solid tumours
BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing Salpingo-Oophorectomy are at Increased Risk of Peritoneal Carcinomatosis
The risk to develop peritoneal carcinomatosis increases over time
ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to Identify Patients Who May Benefit from Further Therapeutic Intervention
Detection of ctDNA using sensitive personalised assays can inform patient prognosis and help guide patient treatment
EMA Recommends Granting a Marketing Authorisation for Tebentafusp
It is intended for the treatment of adult patients with unresectable or metastatic HLA A*02:01 positive uveal melanoma
Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival in Patients with Stage III Colon Cancer
Findings from a post-hoc analysis of IDEA-France
The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer
Patients with cancer, especially haematologic malignancies, are at higher risk for developing breakthrough infections and severe outcomes
Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors
New mechanisms of genomic escape from established covalent and novel non-covalent Bruton’s tyrosine kinase inhibitors described
FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
Safety and efficacy were evaluated in CARTITUDE-1 study
EMA Recommends Granting a Marketing Authorisation for Relugolix
It is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer
A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer Undergoing Thyroidectomy
Findings from the ESTIMABL2 study
First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival Benefit in HR-positive, HER2-negative Advanced Breast Cancer
Findings from the final overall survival analysis in the MONALEESA-2 study